AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Source: bloombergMarkets June 22, 2026 · 07:12
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

The original article opens on the publisher's website.

More from General

View topic →